ReviewJournal of industrial microbiology & biotechnology2016
Discovery and development of surotomycin for the treatment of Clostridium difficile.
Review in Journal of industrial microbiology & biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Identification ofJournal of bacteriology · 2024Article
- Identification of DraRS inJournal of bacteriology · 2023Article
- Article
- Nanomedicine: New Frontiers in Fighting Microbial Infections.Nanomaterials (Basel, Switzerland) · 2023Review
- Genome mining for drug discovery: cyclic lipopeptides related to daptomycin.Journal of industrial microbiology & biotechnology · 2021Article
- Control of the polymyxin analog ratio by domain swapping in the nonribosomal peptide synthetase of Paenibacillus polymyxa.Journal of industrial microbiology & biotechnology · 2020Article
- Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations.Pharmaceutics · 2020Review
- The calcium-dependent lipopeptide antibiotics: structure, mechanism, & medicinal chemistry.MedChemComm · 2019Review
- Article
- Combinatory Therapy Antimicrobial Peptide-Antibiotic to Minimize the Ongoing Rise of Resistance.Frontiers in microbiology · 2019Article
- Advances in the diagnosis and treatment of Clostridium difficile infections.Emerging microbes & infections · 2018Review
- Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment ofFrontiers in microbiology · 2018Review
- Novel Antimicrobials for the Treatment ofFrontiers in medicine · 2018Review
- Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs.Molecules (Basel, Switzerland) · 2017Review
- Gifted microbes for genome mining and natural product discovery.Journal of industrial microbiology & biotechnology · 2017Review
- Clostridium difficile infection: Updates in management.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2017Review
- Antibiotics in the clinical pipeline at the end of 2015.The Journal of antibiotics · 2017Review
- Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.Antimicrobial agents and chemotherapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary challenge for treating Clostridium difficile infections (CDI) is maintenance of clinical response after the end of treatment (sustained clinical response). Disease recurrence following a positive clinical response occurs in approximately 6-25 % of patients after the first episode and in up to 65 % for subsequent recurrences. Surotomycin, a novel cyclic lipopeptide antibiotic with a core derived by Streptomyces roseosporus fermentation, disrupts C. difficile cellular membrane activity in both logarithmic and stationary phases and minimally disturbs normal gastrointestinal microbiota because of its lack of activity against Gram-negative anaerobes and facultative anaerobes. Preclinical and clinical evidence indicate that surotomycin has low oral bioavailability, allowing gastrointestinal tract concentrations to greatly exceed its minimum inhibitory concentration for C. difficile. Surotomycin is well tolerated and effective in hamster models of CDI. Phase 2 clinical evidence suggests that surotomycin (250 mg twice daily) is an effective CDI treatment, with statistically lower recurrence rates than vancomycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.